1. , . Prevalence and genesis of endometriosis. Hum Reprod 1991;6:544–9.
2. , , , et al. Epidemiology of endometriosis in infertile women. Fertil Steril 1995;63:34–8.
3. . Prevalence of endometriosis in asymptomatic women. J Reprod Med 1991;36:513–15.
4. , , , . The prevalence of endometriosis in women with infertile partners. Eur J Obstet Gynecol Reprod Biol 1993;48:135–9.
5. , , , , . Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997;10:199–202.
6. , , . The prevalence of interstitial cystitis, endometriosis, adhesions, and vulvar pain in women with chronic pelvic pain. J Minim Invasive Gynecol 2005;12:43–9.
7. , , , et al. Health-related quality of life burden of women with endometriosis: a literature review. Curr Med Res Opin 2006;22:1787–97.
8. , , , et al. Recognizing endometriosis as a social disease: the European Union-encouraged Italian Senate approach. Fertil Steril 2007;88:1285–7.
9. , , , . Pain, quality of life and complications following the radical resection of rectovaginal endometriosis. BJOG 2004;111:353–6.
10. . Recurrence of endometriosis and its control. Hum Reprod Update 2009;15:441–61.
11. , . Endometriosis. Lancet 2004;364:1789–99.
12. , , . A quantitative overview of controlled trials in endometriosis-associated infertility. Fertil Steril 1993;59:963–76.
13. , , . Laparoscopic surgery in infertile women with minimal or mild endometriosis: Canadian Collaborative Group in Endometriosis. N Engl J Med 1997;337:217–22.
14. . Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Hum Reprod 1999;14:1332–4.
15. , , , et al. Removal of endometriomas before in vitro fertilization does not improve fertility outcomes: a matched, case-control study. Fertil Steril 2004;81:1194–7.
16. , , , , and . Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003;18:1544–52.
17. , , , et al. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci 2002;955:75–85.
18. . Conventional medical therapies for endometriosis. Ann N Y Acad Sci 2002;955:343–52.
19. . Management of endometriosis in fertility patients. Fertil Steril 2004;81:1204–5.
20. , , , . Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003;CD001297.
21. , , . A gonadotropin releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75–9.
22. . Medical therapy of endometriosis. Semin Reprod Med 2003;21:209–22.
23. , , , , . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990;53:998–1003.
24. , , . Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982;37:737–46.
25. . Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand 1993;72:324–36.
26. , . Emerging drugs for endometriosis. Expert Opin Emerg Drugs 2004;9:167–77.
27. . Danazol treatment of endometriosis-associated pain. J Minim Invasive Gynecol 2006;13:523–4.
28. , , . Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68:393–401.
29. , , , et al. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod 2009;24:2504–14.
30. , . Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307–18.
31. , , . Immunologic aspects of endometriosis. Obstet Gynecol Clin North Am 1989;16:93–103.
32. , . Does disruption of immune and endocrine systems by environmental toxins contribute to development of endometriosis? Semin Reprod Endocrinol 1997;15:301–8.
33. , , . Angiogenic factors in endometriosis. Ann NY Acad Sci 2002;955:89–100.
34. , , , et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Hum Reprod 2001;16:1802–8.
35. , , . Reduction of apoptosis and proliferation in endometriosis. Fertil Steril 2004;82:80–5.
36. , , , , . Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681–4.
37. , . Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril 1997;68:585–96.
38. , . COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002;57:768–80.
39. , , , . Characterization of leukocyte subpopulations in the peritoneal fluid of women with endometriosis. Fertil Steril 1988;50:216–22.
40. , . In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13:331–42.
41. , , , . Vascular development in endometriosis. Angiogenesis 2005;8:147–56.
42. , . Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 2007;74:121–30.
43. , , . Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update 1998;4:741–51.
44. , , . Mechanisms and regulation of endometrial angiogenesis. Reprod Med Rev 2002;10:45–61.
45. , . Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997;94:8761–6.
46. , , , et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309–12.
47. , , , . A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629–32.
48. , , , , . Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997;14:2025–32.
49. , , , , . Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet 1996;97:794–9.
50. , , , . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.
51. , , , , . Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am J Physiol 1999;276:858–67.
52. , . Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895–8.
53. . Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995;67:281–316.
54. , , , et al. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–6.
55. , , , , . Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000;5:45–50.
56. , , , et al. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 2005;83:793–5.
57. , , , , . Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008;90:148–55.
58. , . Anti-angiogenic treatment of endometriosis: biochemical aspects. Gynecol Obstet Invest 2004;57:54–6.
59. , , , , . Therapeutic Effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 2002; 909–18.
60. , , , et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003;88:2889–99.
61. , , , et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84:1144–55.
62. , , , et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006;149:137–44.
63. , , , , . Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21:262–8.
64. , , , et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Human Reprod 2009;24:1025–35.
65. , , , et al. Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model. Mol Hum Reprod 2009;15:633–43.
66. , , , et al. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 2006;85:71–7.
67. , , , , . Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor: a novel treatment for endometriosis. Fertil Steril 2004;82:S71.
68. , , , et al. PPARgamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 2005;8:373–9.
69. , , , et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007;88:1108–19.
70. , , , et al. Erythropoietin concentrations are elevated in the peritoneal fluid of women with endometriosis. Hum Reprod 2001;16:945–8.
71. , , , , . Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81–6.
72. , , , et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 2005;146:1301–11.
73. . Angiogenesis drug promising for metastatic colorectal cancer. Lancet 2003;361:1959.
74. , . Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol 2008;181:131–50.
75. , , , et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010;122:1–7.
76. , , . Current clinical trials administering the antiangiogenesis agent SU5416. Oncology 2000;14:1312–23.
77. , , , et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569–74.
78. , , , et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11.
79. , , , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–7.
80. , , , . Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485–534.
81. , , , et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67:426–33.
82. , , , et al. Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi. Trop Doct 2008;38:30–2.
83. , , , . Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333–7.
84. , , , et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791–3.
85. , , , , . Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29–38.
86. , , , et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007;356:39–46.